Adverse effects of ribavirin and outcome in severe acute respiratory syndrome

Experience in two medical centers

Hsueh Erh Chiou, Ching Lung Liu, Mary Jeanne Buttrey, Han Pin Kuo, Hui Wen Liu, Hsu Tah Kuo, Yen Ta Lu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Study objectives: To assess the effect of ribavirin-induced anemia on the outcome of severe acute respiratory syndrome (SARS). Design: A retrospective observational study. Setting: Two medical centers in Taiwan. Patients: Forty-four patients with SARS who received ribavirin and 7 patients with SARS who did not receive ribavirin. Measurements and results: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. The mortality was also higher, but the difference was not statistically significant. On multivariate analysis, hemoglobin level was an independent prognostic correlate of hypoxemia or mortality (odds ratio, 2.0; 95% confidence interval, 1.1 to 3.8; p = 0.03). The hemoglobin began decreasing in two thirds of SARS patients (32 of 44 patients; 73%) who were receiving ribavirin 3 days after therapy with the antiviral drug was started. Patients with a drop in hemoglobin level of > 2 g/dL had a significantly higher mortality rate than the other patients. Hypoxemia developed in one third of SARS patients (17 of 44 patients; 39%) who were receiving ribavirin, all of whom were anemic. Of the 17 hypoxemic patients, 11 (65%) had a drop in hemoglobin of > 2 g/dL, and 4 patients (24%) required a blood transfusion. The mean slope of the hemoglobin decrease was significantly steeper (p = 0.001) in hypoxemic patients with SARS who were receiving ribavirin than in the nonhypoxemic patients with SARS who were receiving ribavirin. Only one of seven SARS patients (14%) who was not receiving ribavirin became anemic, but this individual was not hypoxemic. Eventually, 5 of 17 hypoxemic and anemic SARS patients (29%) who were receiving ribavirin died. The combination of hypoxia with anemia was thus significantly associated with a higher mortality (p < 0.001). Conclusions: Hypoxia combined with anemia increased the risk for death in SARS patients. Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients.

Original languageEnglish
Pages (from-to)263-272
Number of pages10
JournalChest
Volume128
Issue number1
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Severe Acute Respiratory Syndrome
Ribavirin
Hemoglobins
Anemia
Mortality
Coronavirus

Keywords

  • Anemia
  • Hypoxemia
  • Ribavirin
  • Severe acute respiratory syndrome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Adverse effects of ribavirin and outcome in severe acute respiratory syndrome : Experience in two medical centers. / Chiou, Hsueh Erh; Liu, Ching Lung; Buttrey, Mary Jeanne; Kuo, Han Pin; Liu, Hui Wen; Kuo, Hsu Tah; Lu, Yen Ta.

In: Chest, Vol. 128, No. 1, 01.01.2005, p. 263-272.

Research output: Contribution to journalArticle

Chiou, Hsueh Erh ; Liu, Ching Lung ; Buttrey, Mary Jeanne ; Kuo, Han Pin ; Liu, Hui Wen ; Kuo, Hsu Tah ; Lu, Yen Ta. / Adverse effects of ribavirin and outcome in severe acute respiratory syndrome : Experience in two medical centers. In: Chest. 2005 ; Vol. 128, No. 1. pp. 263-272.
@article{a95dbe467384450aa76bf3111f3ae52d,
title = "Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: Experience in two medical centers",
abstract = "Study objectives: To assess the effect of ribavirin-induced anemia on the outcome of severe acute respiratory syndrome (SARS). Design: A retrospective observational study. Setting: Two medical centers in Taiwan. Patients: Forty-four patients with SARS who received ribavirin and 7 patients with SARS who did not receive ribavirin. Measurements and results: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. The mortality was also higher, but the difference was not statistically significant. On multivariate analysis, hemoglobin level was an independent prognostic correlate of hypoxemia or mortality (odds ratio, 2.0; 95{\%} confidence interval, 1.1 to 3.8; p = 0.03). The hemoglobin began decreasing in two thirds of SARS patients (32 of 44 patients; 73{\%}) who were receiving ribavirin 3 days after therapy with the antiviral drug was started. Patients with a drop in hemoglobin level of > 2 g/dL had a significantly higher mortality rate than the other patients. Hypoxemia developed in one third of SARS patients (17 of 44 patients; 39{\%}) who were receiving ribavirin, all of whom were anemic. Of the 17 hypoxemic patients, 11 (65{\%}) had a drop in hemoglobin of > 2 g/dL, and 4 patients (24{\%}) required a blood transfusion. The mean slope of the hemoglobin decrease was significantly steeper (p = 0.001) in hypoxemic patients with SARS who were receiving ribavirin than in the nonhypoxemic patients with SARS who were receiving ribavirin. Only one of seven SARS patients (14{\%}) who was not receiving ribavirin became anemic, but this individual was not hypoxemic. Eventually, 5 of 17 hypoxemic and anemic SARS patients (29{\%}) who were receiving ribavirin died. The combination of hypoxia with anemia was thus significantly associated with a higher mortality (p < 0.001). Conclusions: Hypoxia combined with anemia increased the risk for death in SARS patients. Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients.",
keywords = "Anemia, Hypoxemia, Ribavirin, Severe acute respiratory syndrome",
author = "Chiou, {Hsueh Erh} and Liu, {Ching Lung} and Buttrey, {Mary Jeanne} and Kuo, {Han Pin} and Liu, {Hui Wen} and Kuo, {Hsu Tah} and Lu, {Yen Ta}",
year = "2005",
month = "1",
day = "1",
doi = "10.1378/chest.128.1.263",
language = "English",
volume = "128",
pages = "263--272",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Adverse effects of ribavirin and outcome in severe acute respiratory syndrome

T2 - Experience in two medical centers

AU - Chiou, Hsueh Erh

AU - Liu, Ching Lung

AU - Buttrey, Mary Jeanne

AU - Kuo, Han Pin

AU - Liu, Hui Wen

AU - Kuo, Hsu Tah

AU - Lu, Yen Ta

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Study objectives: To assess the effect of ribavirin-induced anemia on the outcome of severe acute respiratory syndrome (SARS). Design: A retrospective observational study. Setting: Two medical centers in Taiwan. Patients: Forty-four patients with SARS who received ribavirin and 7 patients with SARS who did not receive ribavirin. Measurements and results: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. The mortality was also higher, but the difference was not statistically significant. On multivariate analysis, hemoglobin level was an independent prognostic correlate of hypoxemia or mortality (odds ratio, 2.0; 95% confidence interval, 1.1 to 3.8; p = 0.03). The hemoglobin began decreasing in two thirds of SARS patients (32 of 44 patients; 73%) who were receiving ribavirin 3 days after therapy with the antiviral drug was started. Patients with a drop in hemoglobin level of > 2 g/dL had a significantly higher mortality rate than the other patients. Hypoxemia developed in one third of SARS patients (17 of 44 patients; 39%) who were receiving ribavirin, all of whom were anemic. Of the 17 hypoxemic patients, 11 (65%) had a drop in hemoglobin of > 2 g/dL, and 4 patients (24%) required a blood transfusion. The mean slope of the hemoglobin decrease was significantly steeper (p = 0.001) in hypoxemic patients with SARS who were receiving ribavirin than in the nonhypoxemic patients with SARS who were receiving ribavirin. Only one of seven SARS patients (14%) who was not receiving ribavirin became anemic, but this individual was not hypoxemic. Eventually, 5 of 17 hypoxemic and anemic SARS patients (29%) who were receiving ribavirin died. The combination of hypoxia with anemia was thus significantly associated with a higher mortality (p < 0.001). Conclusions: Hypoxia combined with anemia increased the risk for death in SARS patients. Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients.

AB - Study objectives: To assess the effect of ribavirin-induced anemia on the outcome of severe acute respiratory syndrome (SARS). Design: A retrospective observational study. Setting: Two medical centers in Taiwan. Patients: Forty-four patients with SARS who received ribavirin and 7 patients with SARS who did not receive ribavirin. Measurements and results: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. The mortality was also higher, but the difference was not statistically significant. On multivariate analysis, hemoglobin level was an independent prognostic correlate of hypoxemia or mortality (odds ratio, 2.0; 95% confidence interval, 1.1 to 3.8; p = 0.03). The hemoglobin began decreasing in two thirds of SARS patients (32 of 44 patients; 73%) who were receiving ribavirin 3 days after therapy with the antiviral drug was started. Patients with a drop in hemoglobin level of > 2 g/dL had a significantly higher mortality rate than the other patients. Hypoxemia developed in one third of SARS patients (17 of 44 patients; 39%) who were receiving ribavirin, all of whom were anemic. Of the 17 hypoxemic patients, 11 (65%) had a drop in hemoglobin of > 2 g/dL, and 4 patients (24%) required a blood transfusion. The mean slope of the hemoglobin decrease was significantly steeper (p = 0.001) in hypoxemic patients with SARS who were receiving ribavirin than in the nonhypoxemic patients with SARS who were receiving ribavirin. Only one of seven SARS patients (14%) who was not receiving ribavirin became anemic, but this individual was not hypoxemic. Eventually, 5 of 17 hypoxemic and anemic SARS patients (29%) who were receiving ribavirin died. The combination of hypoxia with anemia was thus significantly associated with a higher mortality (p < 0.001). Conclusions: Hypoxia combined with anemia increased the risk for death in SARS patients. Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients.

KW - Anemia

KW - Hypoxemia

KW - Ribavirin

KW - Severe acute respiratory syndrome

UR - http://www.scopus.com/inward/record.url?scp=22244469109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244469109&partnerID=8YFLogxK

U2 - 10.1378/chest.128.1.263

DO - 10.1378/chest.128.1.263

M3 - Article

VL - 128

SP - 263

EP - 272

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -